Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Berdazimer→

Berdazimer Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not verified
Molecular formula
Not verified
Molecular weight
Not verified g/mol
Drug class
Topical nitric oxide (NO)-releasing agentdermatologic anti-molluscum preparation
Mechanism of action
Berdazimer releases nitric oxide locally. The US prescribing information states that the mechanism of action for treatment of molluscum contagiosum is unknown; no more specific antiviral or immunological pathway should be asserted as established.
Indications / reported uses
  • Topical treatment of molluscum contagiosum in adults and paediatric patients aged 1 year and older under the US FDA ZELSUVMI indication; apply to lesions only according to product instructions

Sources: NLM DailyMed — ZELSUVMI (berdazimer), official label · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Berdazimer Environmental Risk Assessment (ERA) (the Berdazimer ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.